Achini Dingman, MD
Rheumatology · Meridian, IDNPI 1174594758
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,755 of the $2,022 with a category attached, or 86.8%. 15 manufacturers reported payments, led by Amgen at 40.1% of the total.
Across 135 payments — averaging $14.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$811
- UCB, Inc.$319
- Johnson & Johnson$254
- Sobi, Inc$149
- Regeneron Healthcare Solutions, Inc.$129
- Pfizer$92
- plus $269 from 9 others
Across 5 payments — averaging $7060.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$35K
What the payments were for
- Food & beverage$1,75587%
- Education$26713%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 64 | $811 |
| UCB, Inc. | 35 | $319 |
| Johnson & Johnson | 5 | $254 |
| Sobi, Inc | 1 | $149 |
| Regeneron Healthcare Solutions, Inc. | 4 | $129 |
| Pfizer | 6 | $92 |
| AbbVie | 4 | $61 |
| E.r. Squibb & Sons, L.L.C. | 4 | $55 |
| Genentech USA, Inc. | 3 | $39 |
| Bristol Myers Squibb | 2 | $33 |
| Organon | 3 | $25 |
| GSK | 1 | $19 |
| AstraZeneca | 1 | $13 |
| Lilly USA, LLC | 1 | $12 |
| Radius Health, Inc. | 1 | $11 |
How this compares
$2,022 in reported general payments places this provider in the 60th percentile of 28 rheumatology providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Leflunomide | 85 | $8,476 |
| MethotrexateMethotrexate Sodium | 276 | $6,933 |
| Hydroxychloroquine Sulfate | 166 | $5,550 |
| Mycophenolate Mofetil | 17 | $3,596 |
| Sulfasalazine | 77 | $2,286 |
| Methylprednisolone | 76 | $2,177 |
| Sulfasalazine DrSulfasalazine | 41 | $2,141 |
| Celecoxib | 16 | $1,680 |
| Azathioprine | 53 | $1,453 |
| Etodolac | 22 | $1,163 |
| Prednisone | 224 | $1,153 |
| Folic Acid | 81 | $803 |
| Ibuprofen | 30 | $577 |
| Methotrexate SodiumMethotrexate Sodium/Pf | 17 | $330 |
| Diclofenac Sodium | 14 | $268 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Meridian
- Francis NardellaMeridian$3K
- Chara SolichMeridian$2K
- Alma LeairdMeridian$955
- Svetlana MeierMeridian$792
- Sarah DillMeridian$741
- Jacob WelchMeridian$200
- Mikael LagwinskiMeridian$136
- Elizabeth SolowMeridian$41
- Dustin DinningCoeur D Alene$311K
- William KnibbeBoise$164K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.